Biochemical outcome of small-volume or insignificant prostate cancer treated with radical prostatectomy in Japanese population

International Journal of Clinical Oncology

Volumn 17, Issue 2, 2012, Pages 119-123

  Hashimoto, Yasuhiro ^a,b   Okamoto, Akiko ^a,b   Imai, Atsushi ^a,b   Yoneyama, Tohru ^a   Hatakeyama, Shingo ^a   Yoneyama, Takahiro ^a   Koie, Takuya ^a   Kaminura, Noritaka ^a   Ohyama, Chikara ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b Hirosaki Hospital   (Japan)

Author keywords

Insignificant cancer; Prostate cancer; Small volume cancer; Tumor volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CRYOTHERAPY; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME;

AGED; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; TUMOR BURDEN;

EID: 84862855228     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0267-6     Document Type: Article

References (29)

1. Galper SL, Chen MH, Catalona WJ et al (2006) Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 175:907-912
2. Dong F, Reuther AM, Magi-Galluzzi C et al (2007) Pathologic stage migration has slowed in the late PSA era. Urology 70:839-842
3. Noldus J, Graefen M, Haese A et al (2000) Stage migration in clinically localized prostate cancer. Eur Urol 38:74-78
4. Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25:3-9
5. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
6. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732
7. Lawrentschuk N, Klotz L (2010) Active surveillance for favorable-risk prostate cancer: a short review. Korean J Urol 51:665-670
8. Choo R, Klotz L, Danjoux C et al (2002) Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 167:1664-1669
9. Onik G, Barzell W (2008) Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy. Urol Oncol 26:506-510
10. Weinreb JC, Blume JD, Coakley FV et al (2009) Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 251:122-133
11. Ahmed HU, Zacharakis E, Dudderidge T et al (2009) High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer 101:19-26
12. Pisters LL (2010) Cryotherapy for prostate cancer: ready for prime time? Curr Opin Urol 20:218-222
13. Arumainayagam N, Moore CM, Ahmed HU et al (2010) Photo-dynamic therapy for focal ablation of the prostate. World J Urol 28:571-576
14. Stamey TA, Freiha FS, McNeal JE et al (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71:933-938
15. Epstein JI, Chan DW, Sokoll LJ et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407-2411
16. van Oort IM, Kok DE, Kiemeney LA et al (2009) A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or ''insignificant''. Urol Oncol 27:509-513
17. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
18. Noguchi M, Stamey TA, McNeal JE et al (2000) Assessment of morphometric measurements of prostate carcinoma volume. Cancer 89:1056-1064
19. International Union Against Cancer (UICC) (2002) TNM Classification of malignant tumors, 6th edn. In: Sobin LH, Wittekind CH (ed) Wiley-Liss, New York, pp 184-187
20. Khan MA, Partin AW, Mangold LA et al (2003) Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 62:866-871
21. Sim HG, Telesca D, Culp SH et al (2008) Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence. J Urol 179:1775-1779
22. Stamey TA, McNeal JE, Yemoto CM et al (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400
23. Eichelberger LE, Koch MO, Eble JN et al (2005) Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer. Mod Pathol 18:886-890
24. Nelson BA, Shappell SB, Chang SS et al (2006) Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer. BJU Int 97:1169-1172
25. Kikuchi E, Scardino PT, Wheeler TM et al (2004) Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol 172:508-511
26. Epstein JI, Walsh PC, Carmichael M et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271:368-374
27. Dong F, Reuther AM, Magi-Galluzzi C et al (2007) Pathologic stage migration has slowed in the late PSA era. Urology 70:839-842
28. Kattan MW, Eastham JA, Wheeler TM et al (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170:1792-1797
29. Singh H, Canto EI, Shariat SF et al (2004) Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 171:1089-1092